Intestinal microbiota and blue baby syndrome probiotic therapy for term neonates with cyanotic congenital heart disease

Gut Microbes

Volumn 1, Issue 6, 2010, Pages

  Ellis, Collin L ^a,b   Rutledge, John C ^a,b   Underwood, Mark A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Biotechnology and Biophotonics   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bifidobacterium; Cyanotic congenital heart disease; Intestinal microbiota; Necrotizing enterocolitis; Probiotic

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL GROWTH; BLUE BABY SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CYANOTIC HEART DISEASE; HOSPITAL INFECTION; HUMAN; INFANT MORTALITY; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; MULTIPLE ORGAN FAILURE; NECROTIZING ENTEROCOLITIS; NONHUMAN; PATHOPHYSIOLOGY; PREMATURITY; REVIEW; SEPTIC SHOCK; BACTERIUM; CYANOSIS; DIET; GASTROINTESTINAL TRACT; GROWTH, DEVELOPMENT AND AGING; HEART DISEASE; IMMUNOLOGY; INCIDENCE; METABOLISM; METHODOLOGY; MICROBIOLOGY; NEWBORN; PATHOLOGY;

BIFIDOBACTERIUM;

BACTERIA; CYANOSIS; DIET; ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL TRACT; HEART DISEASES; HUMANS; INCIDENCE; INFANT, NEWBORN; PROBIOTICS;

EID: 79251494431     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.6.14077     Document Type: Review

References (109)

1. Blalock A, Taussig HB. Landmark article May 19, 1945: The surgical treatment of malformations of the heart in which there is pulmonary stenosis or pulmonary atresia. By Blalock A, Taussig HB. JAMA 1984; 27:251:2123-38.
2. Pigula FA, Khalil PN, Mayer JE, del Nido PJ, Jonas RA. Repair of tetralogy of Fallot in neonates and young infants. Circulation 1999; 100:157-61.
3. Murphy AM, Cameron DE. The Blalock-Taussig- Thomas collaboration: a model for medical progress. JAMA 2008; 300:328-30.
4. Williams JA, Bansal AK, Kim BJ, Nwakanma LU, Patel ND, Seth AK, et al. Two thousand Blalock-Taussig shunts: a six-decade experience. Ann Thorac Surg 2007; 84:2070-5.
5. Lin PW, Nasr TR, Stoll BJ. Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention. Semin Perinatol 2008; 32:70-82.
6. Hunter CJ, Podd B, Ford HR, Camerini V. Evidence vs. experience in neonatal practices in necrotizing enterocolitis. J Perinatol 2008; 28:9-13.
7. Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet 2006; 368:1271-83.
8. Stoll BJ. Epidemiology of necrotizing enterocolitis. Clin Perinatol 1994; 21:205-18.
9. Blakely ML, Lally KP, McDonald S, Brown RL, Barnhart DC, Ricketts RR, et al. NEC Subcommittee of the NICHD Neonatal Research Network. Postoperative outcomes of extremely low birth-weight infants with necrotizing enterocolitis or isolated intestinal perforation: a prospective cohort study by the NICHD Neonatal Research Network. Ann Surg 2005; 241:984-9.
10. Emami CN, Petrosyan M, Giuliani S, Williams M, Hunter C, Prasadarao NV, et al. Role of the host defense system and intestinal microbial flora in the pathogenesis of necrotizing enterocolitis. Surg Infect (Larchmt) 2009; 10:407-17.
11. Neu J, Mshvildadze M, Mai V. A roadmap for understanding and preventing necrotizing enterocolitis. Curr Gastroenterol Rep 2008; 10:450-7.
12. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjöberg J, Amir E, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11:76-83.
13. Westerbeek EA, van den Berg A, Lafeber HN, Knol J, Fetter WP, van Elburg RM. The intestinal bacterial colonisation in preterm infants: a review of the literature. Clin Nutr 2006; 25:361-8.
14. Wang Y, Hoenig JD, Malin KJ, Qamar S, Petrof EO, Sun J, et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J 2009; 3:944-54.
15. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33:179-201.
16. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network 1993-1994. Pediatrics 2000; 105:1216-26.
17. Stout G, Lambert DK, Baer VL, Gordon PV, Henry E, Wiedmeier SE, et al. Necrotizing enterocolitis during the first week of life: a multicentered case-control and cohort comparison study. J Perinatol 2008; 28:556-60.
18. Grave GD, Nelson SA, Walker WA, Moss RL, Dvorak B, Hamilton FA, et al. New therapies and preventive approaches for necrotizing enterocolitis: report of a research planning workshop. Pediatr Res 2007; 62:510-4.
19. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O'Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol 2007; 27:428-33.
20. Boyd CA, Quigley MA, Brocklehurst P. Donor breast milk versus infant formula for preterm infants: systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2007; 92:169-75.
21. Bury RG, Tudehope D. Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants. Cochrane Database Syst Rev 2001; 405.
22. Carrion V, Egan EA. Prevention of neonatal necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 1990; 11:317-23.
23. Dvorak B. Milk epidermal growth factor and gut protection. J Pediatr 2010; 156:31-5.
24. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007; 369:1614-20.
25. Alfaleh K, Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2008; 5496.
26. Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122:693-700.
27. Caplan MS. Probiotic and prebiotic supplementation for the prevention of neonatal necrotizing enterocolitis. J Perinatol 2009; 29:2-6.
28. Walker WA, Sherman P, Shneider BL, Cohen M, Barnard J. State of research in pediatric gastroenterology, hepatology and nutrition: 2010 and beyond. Gastroenterology 2010; 138:411-6.
29. Bolisetty S, Lui K, Oei J, Wojtulewicz J. A regional study of underlying congenital diseases in term neonates with necrotizing enterocolitis. Acta Paediatrica 2000; 89:1226-30.
30. Giannone PJ, Luce WA, Nankervis CA, Hoffman TM, Wold LE. Necrotizing enterocolitis in neonates with congenital heart disease. Life Sci 2008; 82:341-7.
31. Ostlie DJ, Spilde TL, St. Peter SD, Sexton N, Miller KA, Sharp RJ, et al. Necrotizing enterocolitis in fullterm infants. J Pediatr Surg 2003; 38:1039-42.
32. McElhinney DB, Hedrick HL, Bush DM, Pereira GR, Stafford PW, Gaynor JW. Necrotizing enterocolitis in neonates with congenital heart disease: risk factors and outcomes. Pediatrics 2000; 106:1080-7.
33. Ozek E, Soll R, Schimmel MS. Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia. Cochrane Database Syst Rev 2010; 5089.
34. Raboei EH. Necrotizing enterocolitis in full-term neonates: is it aganglionosis? Eur J Pediatr Surg 2009; 19:101-4.
35. Lambert DK, Christensen RD, Henry E, Besner GE, Baer VL, Wiedmeier SE, et al. Necrotizing enterocolitis in term neonates: data from a multihospital health-care system. J Perinatol 2007; 27:437-43.
36. Maayan-Metzger A, Itzchak A, Mazkereth R, Kuint J. Necrotizing enterocolitis in full-term infants: casecontrol study and review of the literature. J Perinatol 2004; 24:494-9.
37. Leung MP, Chau KT, Hui PW, Tam AY, Chan FL, Lai CL, et al. Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. J Pediatr 1988; 113:1044-6.
38. Yang YH, Yau KI, Wu MH, Tang JR. Cyanotic congenital heart disease and necrotizing enterocolitis: report of three cases. Acta Paediatrica Taiwanica 1999; 40:348-50.
39. Cheng W, Leung MP, Tam PK. Surgical intervention in necrotizing enterocolitis in neonates with symptomatic congenital heart disease. Pediatr Surg Int 1999; 15:492-5.
40. American Heart Association. Common Congenital Cardiovascular Defects. Single-Ventricle Defects. http://www.americanheart.org/presenter.jhtml?identifier=11072#HLHS; accessed 1 February 2010.
41. American Heart Association. Common Congenital Cardiovascular Defects. Truncus Arteriosus. http://www.americanheart.org/presenter.jhtml?identifier=11073; accessed 1 February 2010.
42. Abreu MT. The Ying and Yang of bacterial signaling in necrotizing enterocolitis. Gastroenterology 2010; 138:39-43.
43. Frost BL, Jilling T, Caplan MS. The importance of pro-inflammatory signaling in neonatal necrotizing enterocolitis. Semin Perinatol 2008; 32:100-6.
44. Anand RJ, Leaphart CL, Mollen KP, Hackam DJ. The role of the intestinal barrier in the pathogenesis of necrotizing enterocolitis. Shock 2007; 27:124-33.
45. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviraltreated HIV infection. J Infect Dis 2009; 199:1177-85.
46. Chan KL, Wong KF, Luk JM. Role of LPS/CD14/ TLR4-mediated inflammation in necrotizing enterocolitis: pathogenesis and therapeutic implications. World J Gastroenterol 2009; 15:4745-52.
47. El-Assal ON, Radulescu A, Besner GE. Heparinbinding EGF-like growth factor preserves mesenteric microcirculatory blood flow and protects against intestinal injury in rats subjected to hemorrhagic shock and resuscitation. Surgery 2007; 142:234-42.
48. Urao M, Teitelbaum DH, Drongowski RA, Coran AG. The association of gut-associated lymphoid tissue and bacterial translocation in the newborn rabbit. J Pediatr Surg 1996; 31:1482-7.
49. Zaneveld JR, Lozupone C, Gordon JI, Knight R. Ribosomal RNA diversity predicts genome diversity in gut bacteria and their relatives. Nucleic Acids Res 2010; 38:3869-79.
50. Wu D, Hugenholtz P, Mavromatis K, Pukall R, Dalin E, Ivanova NN. A phylogeny-driven genomic encyclopedia of Bacteria and Archaea. Nature 2009; 462:1056-60.
51. Weng L, Rubin EM, Bristow J. Application of sequence-based methods in human microbial ecology. Genome Res 2006; 16:316-22.
52. Hecht G, Riedmann EM. Exciting times for gastrointestinal microbiology. Gut Microbes 2010; 1:1-2.
53. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65.
54. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, et al. The NIH Human Microbiome Project. Genome Res 2009; 19:2317-23.
55. Dittmar E, Beyer P, Fischer D, Schäfer V, Schoepe H, Bauer K, et al. Necrotizing enterocolitis of the neonate with Clostridium perfringens: diagnosis, clinical course and role of alpha toxin. Eur J Pediatr 2008; 167:891-5.
56. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83:460-9.
57. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136:65-80.
58. Hodges K, Gill R. Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbes 2010; 1:4-21.
59. Santos RL, Raffatellu M, Bevins CL, Adams LG, Tükel C, Tsolis RM, et al. Life in the inflamed intestine, Salmonella style. Trends Microbiol 2009; 17:498-506.
60. Crawford PA, Crowley JR, Sambandam N, Muegge BD, Costello EK, Hamady M, et al. Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci USA 2009; 106:11276-81.
61. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101:15718-23.
62. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to dietinduced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104:979-84.
63. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-3.
64. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1:6-14.
65. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137:1716-24
66. Kandil ME, Elwan A, Hussein Y, Kandeel W, Rasheed M. Ghrelin levels in children with congenital heart disease. J Trop Pediatr 2009; 55:307-12.
67. Bernstein D, Bell JG, Kwong L, Castillo RO. Alterations in postnatal intestinal function during chronic hypoxemia. Pediatr Res 1992; 31:234-8.
68. Farahani R, Kanaan A, Gavrialov O, Brunnert S, Douglas RM, Morcillo P, et al. Differential effects of chronic intermittent and chronic constant hypoxia on postnatal growth and development. Pediatr Pulmonol 2008; 43:20-8.
69. Moromisato DY, Moromisato MY, Zanconato S, Roberts CT Jr. Effect of hypoxia on lung, heart and liver insulin-like growth factor-I gene and receptor expression in the newborn rat. Crit Care Med 1996; 24:919-24.
70. Mortola JP, Xu LJ, Lauzon AM. Body growth, lung and heart weight and DNA content in newborn rats exposed to different levels of chronic hypoxia. Can J Physiol Pharmacol 1990; 68:1590-4.
71. Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M. Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 1997; 76:101-7.
72. Underwood MA, Salzman NH, Bennett SH, Barman M, Mills DA, Marcobal A, et al. A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota and fecal short-chain fatty acids. J Pediatr Gastroenterol Nutr 2009; 48:216-25.
73. Joint Food and Agriculture Organization of the United Nations/World Health Organization expert consultation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, October 2001; http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf, accessed 27 January 2009.
74. Sanders ME. How do we know when something called "probiotic" is really a probiotic? A guideline for consumers and health care professionals. Functional Food Reviews 2009; 1:3-12; DOI 10.2310/6180.2009.00002.
75. Kalliomäki M, Antoine JM, Herz U, Rijkers GT, Wells JM, Mercenier A. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of allergic diseases by probiotics. J Nutr 2010; 140:713-21.
76. Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr 2010; 140:690-7.
77. Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 2010; 140:698-712.
78. Rabot S, Rafter J, Rijkers GT, Watzl B, Antoine JM. Guidance for substantiating the evidence for beneficial effects of probiotics: impact of probiotics on digestive system metabolism. J Nutr 2010; 140:677-89.
79. Chen CC, Kong MS, Lai MW, Chao HC, Chang KW, Chen SY, et al. Probiotics have clinical, microbiologic and immunologic efficacy in acute infectious diarrhea. Pediatr Infect Dis J 2010; 29:135-8.
80. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007; 119:124-30.
81. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007; 6475.
82. Alfaleh K, Anabrees J, Bassler D. Probiotics reduce the risk of necrotizing enterocolitis in preterm infants: a meta-analysis. Neonatology 2010; 97:93-9.
83. Sethi T. Probiotics in pediatric care. Explore (NY) 2009; 5:245-9.
84. Sela DA, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, et al. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci USA 2008; 105:18964-9.
85. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 2010; 8:171-84.
86. Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ, et al. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med 2009; 47:1205-11.
87. Ventura M, O'Flaherty S, Claesson MJ, Turroni F, Klaenhammer TR, van Sinderen D, et al. Genomescale analyses of health-promoting bacteria: probiogenomics. Nat Rev Microbiol 2009; 7:61-71.
88. Lin PW, Nasr TR, Berardinelli AJ, Kumar A, Neish AS. The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. Pediatr Res 2008; 64:511-6.
89. Bäckhed F, Crawford PA. Coordinated regulation of the metabolome and lipidome at the host-microbial interface. Biochimica Et Biophysica Acta 2010; 1801:240-5.
90. Kumar A, Wu H, Collier-Hyams LS, Kwon YM, Hanson JM, Neish AS. The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 2009; 182:538-46.
91. Fava F, Lovegrove JA, Gitau R, Jackson KG, Tuohy KM. The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. Curr Med Chem 2006; 13:3005-21.
92. de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71:405-11.
93. Girard SA, Bah TM, Kaloustian S, Lada-Moldovan L, Rondeau I, Tompkins TA, et al. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br J Nutr 2009; 102:1420-5.
94. Shane AL, Cabana MD, Vidry S, Merenstein D, Hummelen R, Ellis CL, et al. Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes 2010; 1:243-53.
95. Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach JT, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes 2010; 1:164-85.
96. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122:8-12.
97. Vlieger AM, Robroch A, van Buuren S, Kiers J, Rijkers G, Benninga MA, et al. Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebioticcontaining infant formula: a randomised controlled trial. Br J Nutr 2009; 102:869-75.
98. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005; 24:31-40.
99. Lherm T, Monet C, Nougière B, Soulier M, Larbi D, Le Gall C, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002; 28:797-801.
100. Sullivan A, Nord CE. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 2006; 38:327-31.
101. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35:1155-60.
102. Yamazaki S, Machii K, Tsuyuki S, Momose H, Kawashima T, Ueda K. Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion. Immunology 1985; 56:43-50.
103. Abe F, Muto M, Yaeshima T, Iwatsuki K, Aihara H, Ohashi Y, et al. Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. Anaerobe 2010; 16:131-6.
104. McNaught CE, Woodcock NP, MacFie J, Mitchell CJ. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut 2002; 51:827-31.
105. Liu C, Zhang ZY, Dong K, Yuan JP, Guo XK. Antibiotic resistance of probiotic strains of lactic acid bacteria isolated from marketed foods and drugs. Biomed Environ Sci 2009; 22:401-12.
106. Kiwaki M, Sato T. Antimicrobial susceptibility of Bifidobacterium breve strains and genetic analysis of streptomycin resistance of probiotic B. breve strain Yakult. Int J Food Microbiol 2009; 134:211-5.
107. Marcobal A, Underwood MA, Mills DA. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr 2008; 46:608-11.
108. Walker AW, Duncan SH, Harmsen HJ, Holtrop G, Welling GW, et al. The species composition of the human intestinal microbiota differs between particleassociated and liquid phase communities. Environ Microbiol 2008; 10:3275-83.
109. Hartman AL, Lough DM, Barupal DK, Fiehn O, Fishbein T, Zasloff M, et al. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci USA 2009; 106:17187-92.